製品番号: HY-16214

FX-11

(別名: LDHA Inhibitor FX11)

31 Cited Publications

カスタマーレビュー

Based on 31 publication(s) in Google Scholar

FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.21%
CAS 番号: 213971-34-7
分子式: C₂₂H₂₂O₄
分子量:350.41

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year

FX-11 構造式

CAS 番号: 213971-34-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (31)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

IC50: 23.3 μM (LDHA in HeLa cell) ^[1].

体外実験

FX-11 (9 μM, 24-48 h) shows activation of AMP kinase and phosphorylation of its substrate acetyl-CoA carboxylase^[2].
FX-11 (0-100 μM, 72 h) inhibits cell proliferation in BxPc-3 and MIA PaCa-2 cells^[3].
FX-11 inhibits glycolysis and alters cellular energy metabolism in P493 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

P493 cells
Concentration:

9 μM
Incubation Time:

24 h, 48 h
Result:

Showed a decrease in ATP levels, accompanied by activation of AMP kinase and phosphorylation of its substrate acetyl-CoA carboxylase.

Cell Proliferation Assay^[3]

Cell Line:

BxPc-3 and MIA PaCa-2 cells
Concentration:

0-100 µM
Incubation Time:

72 h
Result:

Reduced cell metabolic activity in a concentration-dependent manner, showed a significant reduction in cell proliferation, with IC₅₀ values of 49.27 µM and 60.54 µM for BxPc-3 and MIA PaCa-2 cells, respectively.

体内実験

FX-11 (42 μg/mouse; IP, daily for 10-14 days) inhibits P493 tumor growth^[2].
FX-11 (0-2 mg/kg, IP, daily, for 3 weeks) significantly delays tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male SCID mice and RH-Foxn1nu mice (human P493 B-cell xenografts)^[2]
Dosage:

42 µg/mouse (2.1 mg/kg)
Administration:

IP; daily for 10-14 days
Result:

Resulted in a remarkable inhibition of tumor growth, inhibited tumor xenograft progression.

Animal Model:

Immunocompromised CD-1 mice (6-8 weeks; 20-25 g, n=5 per group)^[3]
Dosage:

2 mg/kg, 1 mg/kg+15 mg/kg TEPP-46, 2 mg/kg+30 mg/kg TEPP-46
Administration:

IP (100 µL), daily, for 3 weeks
Result:

Significantly lowered LDHA activity in plasma and tumor lysates; significantly lowered the expression of the proliferation marker Ki-67; significantly decreased proliferation indices were observed in tumor sections; significantly delayed tumor growth.

化学情報

CAS 番号 213971-34-7
性状 Solid
分子量 350.41
分子式 C₂₂H₂₂O₄
Color White to off-white
SMILES

O=C(C1=C2C=C(CC3=CC=CC=C3)C(C)=CC2=C(CCC)C(O)=C1O)O
別名

LDHA Inhibitor FX11
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (31)

All Cell Proliferation/Viability AssayCell Imaging/StainingIn Vivo Efficacy StudyIn Vivo ImagingRT-PCR

Sort by:

Journal Impact Factor

Cell Metab

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. [Abstract]

2021 Jan 5;33(1):51-64.e9. PMID: 33181091

FX-11 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):51-64.e9. [Abstract]

Dose-response curves for FX-11 (0-100 μM; 72 hours). Results of cell viability assays in five organoid models derived from TNBC patients.

FX-11 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):51-64.e9. [Abstract]

FX-11 (11.1 μM; 5–6 days). Representative bright-field images of organoids from three selected cases after drug treatment.

FX-11 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):51-64.e9. [Abstract]

The effect of anti-LDH antibody FX-11 (2 mg/kg; twice a week for 24 days) combined with immune checkpoint inhibitor therapy on TS/A tumor growth.
Immunity

Inhibitory co-receptor Lag3 supports Foxp3+ regulatory T cell function by restraining Myc-dependent metabolic programming. [Abstract]

2024 Aug 23:S1074-7613(24)00407-2. PMID: 39236718
Cell Res

Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation. [Abstract]

2024 Jan;34(1):13-30. PMID: 38163844
Gastroenterology

Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis. [Abstract]

2024 Jan 24:S0016-5085(24)00064-7. PMID: 38272100
Nat Metab

Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer. [Abstract]

2022 Dec;4(12):1830-1846. PMID: 36536137

FX-11 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2022 Dec;4(12):1830-1846. [Abstract]

FX11(1 mg/kg/day; i.p.) in combination with NSC23766 (NSC; 1.5 mg/kg/day; i.p.) for 2-3 weeks, displays a pronounced inhibitory effect on lung metastasis of Hs578T cells .
Nat Commun

Histone lactylation promotes rheumatoid arthritis progression by increasing NFATc2 expression and the production of anti-lactylated histone autoantibodies. [Abstract]

2025 Oct 10;16(1):9034. PMID: 41073397
Autophagy

2026 Jun 12:1-18. PMID: 42283498
Adv Sci (Weinh)

Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]

2024 Jul 9:e2406333. PMID: 38981044
Free Radic Biol Med

p67phox/NOX2 inhibits psoriasis by regulating the HIF-1α-glycolysis axis via p53-AMPK in keratinocytes. [Abstract]

2025 Sep:237:503-514. PMID: 40516795
J Transl Med

Lactylation-induced ALKBH5 targets RNF123 to worsen retinal Müller cell activation through PKM2-regulated Glycolysis in diabetic retinopathy. [Abstract]

2025 Oct 15;23(1):1105. PMID: 41094513
Oncogene

LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer. [Abstract]

2026 May;45(17):1544-1556. PMID: 41922574
Cell Chem Biol

Aerobic glycolysis promotes NLRP3 inflammasome activation via NLRP3 lactylation. [Abstract]

2026 Feb 19;33(2):213-226.e5. PMID: 41643668
Clin Transl Med

Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. [Abstract]

2021 Jun;11(6):e467. PMID: 34185423
J Anim Sci Biotechnol

Proteo-transcriptomic profiles reveal key regulatory pathways and functions of LDHA in the ovulation of domestic chickens (Gallus gallus). [Abstract]

2024 May 10;15(1):68. PMID: 38725063
Fundam Res

Astrocytic pyruvate dehydrogenase kinase-lactic acid axis involvement in glia-neuron crosstalk contributes to morphine-induced hyperalgesia in mice. [Abstract]

2023 Mar 6;4(4):820-828. PMID: 39161415
JCI Insight

Lactate programs CRIP1 protein lactylation to drive synovial proliferation in rheumatoid arthritis. [Abstract]

2026 Jun 8;11(11):e200928. PMID: 42258744
Breast Cancer Res

Hypoxia-mediated repression of pyruvate carboxylase drives immunosuppression. [Abstract]

2024 Jun 7;26(1):96. PMID: 38849928
Biomolecules

4-OI Protects MIN6 Cells from Oxidative Stress Injury by Reducing LDHA-Mediated ROS Generation. [Abstract]

2022 Sep 4;12(9):1236. PMID: 36139075
Mol Cancer Res

Bone Metastatic Progression of Prostate Cancer is Regulated by TRIM28-LDHA Mediated Metabolism. [Abstract]

2025 Oct 17. PMID: 41105391
Int Immunopharmacol

GDF15 attenuates sepsis-induced acute lung injury by suppressing the HIF-1α/LDHA pathway. [Abstract]

2025 Jul 15:163:115198. PMID: 40669249
Int Immunopharmacol

NMAAP1 regulated macrophage polarizion into M1 type through glycolysis stimulated with BCG. [Abstract]

2024 Jan 5:126:111257. PMID: 37988910
J Cell Mol Med

Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial-To-Mesenchymal Transition. [Abstract]

2025 Jul;29(13):e70692. PMID: 40629253
Exp Neurol

Lactate exacerbates neuroinflammation in sepsis-associated encephalopathy via promoting neutrophil migration from skull bone marrow to the meninge. [Abstract]

2025 May 21:115318. PMID: 40409661
FEBS J

Sex-related changes in lactate dehydrogenase A expression differently impact the immune response in melanoma. [Abstract]

2025 Jun;292(12):3056-3071. PMID: 39888245
Sci Rep

Bovine tumor necrosis factor-alpha Increases IL-6, IL-8, and PGE2 in bovine fibroblast-like synoviocytes by metabolic reprogramming. [Abstract]

2023 Feb 24;13(1):3257. PMID: 36828912

FX-11 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2023 Feb 24;13(1):3257. [Abstract]

FX11 (20 μM; pretreat for 1 h) decreases bTNF-α-induced COX-2 mRNA expression and PGE2 synthesis in bovine fibroblast-like synoviocyte.
Mol Med Rep

hCINAP serves a critical role in hypoxia‑induced cardiomyocyte apoptosis via modulating lactate production and mitochondrial‑mediated apoptosis signaling. [Abstract]

2021 Feb;23(2):109. PMID: 33300073
J Periodontal Res

A Novel Gene DUSP8 Missense Mutation Causes Nonsyndromic Hereditary Gingival Fibromatosis by Dysregulating Lysine Lactylation. [Abstract]

2025 Jan 29. PMID: 39887402
bioRxiv

2025 Sep 21.
SSRN

2023 Sep 7.
bioRxiv

2023 Jul 11.
Universidad De Salamanca

2023

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (713.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8538 mL

14.2690 mL

28.5380 mL

5 mM

0.5708 mL

2.8538 mL

5.7076 mL

10 mM

0.2854 mL

1.4269 mL

2.8538 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. EC Calvaresi. Small molecule inhibitors of lactate dehydrogenase a as an anticancer strategy. 2014.

[2]. Le A, et, al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42. [Content Brief]

[3]. Mohammad GH, et al. Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer. Cancers (Basel). 2019 Sep 16;11(9):1372. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8538 mL	14.2690 mL	28.5380 mL	71.3450 mL
	5 mM	0.5708 mL	2.8538 mL	5.7076 mL	14.2690 mL
	10 mM	0.2854 mL	1.4269 mL	2.8538 mL	7.1345 mL
	15 mM	0.1903 mL	0.9513 mL	1.9025 mL	4.7563 mL
	20 mM	0.1427 mL	0.7134 mL	1.4269 mL	3.5672 mL
	25 mM	0.1142 mL	0.5708 mL	1.1415 mL	2.8538 mL
	30 mM	0.0951 mL	0.4756 mL	0.9513 mL	2.3782 mL
	40 mM	0.0713 mL	0.3567 mL	0.7134 mL	1.7836 mL
	50 mM	0.0571 mL	0.2854 mL	0.5708 mL	1.4269 mL
	60 mM	0.0476 mL	0.2378 mL	0.4756 mL	1.1891 mL
	80 mM	0.0357 mL	0.1784 mL	0.3567 mL	0.8918 mL
	100 mM	0.0285 mL	0.1427 mL	0.2854 mL	0.7134 mL

FX-11

31 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

FX-11

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 FX-11

生物活性

化学情報

Publications (31)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

FX-11

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 FX-11

生物活性

化学情報

Publications (31)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

FX-11 関連分類

HY-16214 関連分類